Panama

The primary regulatory authority for health products in Panama is the Direccion Nacional de Farmacia y Drogas (DNFD), operating under the Ministerio de Salud (MINSA). The main governing legislation is Law 1 of January 10, 2001, which establishes the regulatory framework for medicines, medical devices, diagnostics, and related health products. The DNFD is responsible for the registration, authorization, surveillance, and control of all health products marketed in Panama. All products must obtain a Registro Sanitario (sanitary registration) prior to commercialization, and applications are reviewed through a formal dossier submission process managed by DNFD technical evaluators. Digital health products and software as a medical device are increasingly subject to regulatory scrutiny, though specific frameworks for these categories are still evolving.

Applicants must appoint a local legal representative or authorized distributor registered in Panama to submit and maintain product registrations. Panama generally accepts dossiers structured according to the Common Technical Document (CTD) format, and the country is a member of the Pan American Network for Drug Regulatory Harmonization (PANDRH), which facilitates alignment with regional standards. Reference to approvals from stringent regulatory authorities such as the US FDA, EMA, or Health Canada can support accelerated or simplified review pathways for certain product categories. Recent reforms have focused on improving transparency in the registration process, reducing administrative backlogs, and developing clearer pathways for innovative products including diagnostics and digital health tools. Fee structures and renewal requirements are defined by MINSA resolutions and are subject to periodic revision.

Public procurement of health products in Panama is primarily managed through the Caja de Seguro Social (CSS), the national social security system, and MINSA, which together account for the majority of public sector health expenditure. The CSS operates largely independently from MINSA and conducts its own procurement processes for its affiliated population, while MINSA procures for the broader public health network. National tenders are administered through the Panama Compras platform, the government's official electronic public procurement system governed by Law 22 of 2006 and its subsequent amendments. The Contraloria General de la Republica provides oversight and must endorse significant public contracts. Panama is a unitary state, so procurement is centralized at the national level rather than split across regional or state authorities, though some regional health facilities may manage smaller local purchases within established frameworks.

The private sector in Panama is well developed, particularly in Panama City, and represents a significant channel for health product commercialization through private hospitals, clinics, and pharmacy chains. Distributors and importers play a central intermediary role in both public and private channels. Panama benefits from donor-funded health programs, and organizations such as PAHO/WHO, UNICEF, and USAID have historically supported procurement and supply chain strengthening initiatives in the country. The Global Fund has provided support for disease-specific programs including HIV, tuberculosis, and malaria, creating additional procurement channels outside standard government processes. Panama does not impose strong local manufacturing preference policies, as the country has a limited domestic pharmaceutical and device manufacturing base and relies heavily on imports; however, preferential pricing or margin considerations for locally registered or distributed products can arise in tender evaluation criteria.